New drug approvals and pipeline progress are likely to help maintain the momentum for the Zacks Biomedical and Genetics industry despite the uncertain macro environment. A strong portfolio and solid p...

This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 bil...

Here is how Incyte (INCY) and Atara Biotherapeutics (ATRA) have performed compared to their sector so far this year.

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Highlights Commercial Growth, Clinical Progress and 2025 Milestones at the 43rd Annual J.P. Morgan Healthcare Conference.

Incyte's robust growth, led by JAKAFI and OPZELURA, is set to increase with new product launches of MONJUVI, ZYNZY, and NIKTIMVO in 2025. Analysts expect Incyte's revenues to grow by ~10% annually unt...

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Vertex Pharmaceuticals (VRTX). But which of these two stocks presents investors with the bet...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investo...

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) announced today that it will present at the 43rd Annual J. P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 am (PST). The p...

Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and D...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Late-Breaking Tafasitamab (Monjuvi®) Data Demonstrate Significantly Improved Progression-Free Survival in Relapsed or Refractory Follicular Lymphoma...

INCY's phase III study, evaluating retifanlimab in combination with platinum-based chemotherapy for the treatment of metastatic non-small cell lung cancer, meets primary and secondary endpoints.

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (EXEL) and Incyte (INCY). But which of these two stocks is more attractive to value investors?

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in NSCLC.

Incyte (INCY) reported earnings 30 days ago. What's next for the stock?

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will now present at Citi's 2024 Global Healthcare Conference on Tuesday, December 3, 2024 at 8:00 a.m. The presentation ...

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH24--Incyte to Spotlight New Data, Including a Late Breaking Oral Presentation for Tafasitamab in Follicular Lymphoma, at the 2024 ASH Annual Meeting.

INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.

Incyte (INCY) led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.

The biopharmaceutical company provided disappointing updates on two research studies.